Common Side Effects of Cogentin (Benztropine)
Cogentin (benztropine) commonly causes anticholinergic side effects including dry mouth, blurred vision, constipation, urinary retention, confusion, and dizziness, with more severe reactions possible at higher doses or in susceptible patients. 1
Primary Anticholinergic Effects
The FDA drug label clearly identifies the most frequent side effects associated with benztropine mesylate 1:
Common Side Effects:
- Dry mouth (xerostomia)
- Blurred vision and mydriasis (pupil dilation)
- Constipation
- Urinary retention or dysuria (difficulty urinating)
- Dizziness and lightheadedness
- Confusion and nervousness
- Tachycardia (rapid heart rate)
- Nausea and vomiting
Musculoskeletal Effects:
- Muscle weakness - patients may complain of inability to move particular muscle groups, especially with large doses
- When rigid muscles suddenly relax (e.g., neck), patients may experience a sensation of weakness that requires dosage adjustment 1
Serious Adverse Effects
While less common, serious side effects warrant immediate attention 1:
- Visual hallucinations (reported occasionally)
- Mental confusion and excitement (particularly with large doses)
- Toxic psychosis - especially in patients with pre-existing mental disorders taking neuroleptic drugs
- Intensification of mental symptoms in psychiatric patients
- Hyperthermia (elevated body temperature)
- Glaucoma precipitation (particularly angle-closure glaucoma)
Important Clinical Context
Critical caveat from guidelines: Benztropine should be avoided in elderly patients with Alzheimer's disease who develop extrapyramidal symptoms from typical antipsychotics 2. The guidelines explicitly state to "avoid use of benztropine (Cogentin) or trihexyphenidyl (Artane)" in this population, likely due to the compounding cognitive and anticholinergic burden.
Overdose Manifestations
In overdose situations, symptoms mirror atropine poisoning 1:
- CNS depression or stimulation
- Delirium, hallucinations, convulsions
- Severe hyperthermia and anhidrosis (inability to sweat)
- Respiratory arrest
- Cardiovascular effects including elevated blood pressure and tachycardia
- Potential progression to coma and shock
High-Risk Populations
Patients requiring closer monitoring 1:
- Those with tachycardia tendency
- Prostatic hypertrophy (urinary retention risk)
- Mental disorders (risk of toxic psychosis)
- Angle-closure glaucoma (contraindicated)
- Pediatric patients (use with caution due to atropine-like effects)
Practical Management
The cumulative action of benztropine necessitates continued supervision 1. Side effects are dose-dependent, and many can be managed through dosage adjustment rather than discontinuation. However, the drug's anticholinergic burden makes it problematic in elderly populations and those with cognitive impairment, where alternative management strategies for extrapyramidal symptoms should be prioritized.